Display Settings:

Format

Send to:

Choose Destination
    Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10920-5. Epub 2010 Jun 1.

    Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected].

    Source

    Department of Pathology, Moores Cancer Center, University of California, La Jolla, CA 92093, USA.

    Erratum in

    • Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13556.

    Abstract

    Regulation of the actin-myosin cytoskeleton plays a central role in cell migration and cancer progression. Here, we report the discovery of a cytoskeleton-associated kinase, pseudopodium-enriched atypical kinase 1 (PEAK1). PEAK1 is a 190-kDa nonreceptor tyrosine kinase that localizes to actin filaments and focal adhesions. PEAK1 undergoes Src-induced tyrosine phosphorylation, regulates the p130Cas-Crk-paxillin and Erk signaling pathways, and operates downstream of integrin and epidermal growth factor receptors (EGFR) to control cell spreading, migration, and proliferation. Perturbation of PEAK1 levels in cancer cells alters anchorage-independent growth and tumor progression in mice. Notably, primary and metastatic samples from colon cancer patients display amplified PEAK1 levels in 81% of the cases. Our findings indicate that PEAK1 is an important cytoskeletal regulatory kinase and possible target for anticancer therapy.

    PMID:
    20534451
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2890752
    Free PMC Article

    Images from this publication.See all images (4) Free text

    Fig. 1.
    Fig. 3.
    Fig. 2.
    Fig. 4.

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk